Neumora Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(67,992) | $(53,721) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 9,324 | 7,373 |
| Non-cash operating lease expense | 877 | 791 |
| Depreciation and amortization | 157 | 158 |
| Net accretion of investments in marketable securities | (1,289) | (1,147) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 966 | 7,351 |
| Accounts payable | (2,255) | 1,155 |
| Accrued liabilities | 1,679 | (4,113) |
| Operating lease liabilities | (915) | (802) |
| Net cash used in operating activities | (59,448) | (42,955) |
| Investing activities: | ||
| Purchases of marketable securities | (44,385) | (185,804) |
| Cash paid for acquisition of assets | — | (775) |
| Proceeds from maturities of marketable securities | 88,545 | 36,578 |
| Net cash provided by (used in) investing activities | 44,160 | (150,001) |
| Financing activities: | ||
| Proceeds from exercise of stock options | — | 1,845 |
| Net cash provided by financing activities | — | 1,845 |
| Net change in cash and cash equivalents and restricted cash | (15,288) | (191,111) |
| Cash and cash equivalents and restricted cash at beginning of year | 143,361 | 375,251 |
| Cash and cash equivalents and restricted cash at end of period | $128,073 | $184,140 |
| Components of cash and restricted cash: | ||
| Cash and cash equivalents | $126,860 | $182,927 |
| Restricted cash | 1,213 | 1,213 |
| Total cash and cash equivalents and restricted cash | $128,073 | $184,140 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.